Sorrento Therapeutics Inc (SRNE)

[dia76ca]

We can expect SEMDEXA news any day now. But we should examine the good news about ABIVERTINIB and Mpro.
All three of these drugs have multi-billion sales potential.
And all 3 could produce revenue beginning in 2023.
But the interesting thing about ABIVERTINIB and Mpro is that they both have advanced studies in China. Mpro is already in Covid patients in China and ABIVERTINIB is very close to marketing approval in China!
Sorrento's strategy is to market both in China (1.5 billion population) and Latin America (600 million population) before moving on to Europe (700 million population) and the US (333 million population).
But WHO WILL BE Sorrento's MARKETING PARTNER in all these territories? And which cash rich BP might be interested in a buyout to acquire these 3 large income producers as early as next year? We have been told partnering discussions about ABIVERTINIB have been going on for some time. It is unlikely that the discussions have not expanded to the wider portfolio IMO!